LAWRENCE ALAN MENDELSOHN MD NPI 1295717189

NPI Details

Lawrence Alan Mendelsohn, MD is a hematology and oncology internal medicine in Little Rock, AR with 46 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Lawrence Alan Mendelsohn, MD NPI is 1295717189. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF ARKANSAS COLLEGE OF MEDICINE
Graduation Year:1980

The provider's business location address is:

8901 CARTI WAY
LITTLE ROCK, AR
ZIP 72205-523
Phone: (501) 219-8777
Fax: (501) 907-6522

The NPI 1295717189 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Uric acid level, blood (HCPCS:84550)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Ferritin (blood protein) level (HCPCS:82728)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, decitabine, 1 mg (HCPCS:J0894)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Unclassified drugs (HCPCS:J3490)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Nephelometry, test method using light (HCPCS:83883)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Magnesium level (HCPCS:83735)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Protein measurement, serum (HCPCS:84165)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Blood test, clotting time (HCPCS:85610)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Vitamin d-3 level (HCPCS:82306)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Rheumatoid factor level (HCPCS:86431)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Erythropoietin (protein) level (HCPCS:82668)
• Iron level (HCPCS:83540)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Iron binding capacity (HCPCS:83550)
• Drawing of blood for a medical problem (HCPCS:99195)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Automated urinalysis test (HCPCS:81003)
• Thyroxine (thyroid chemical), total (HCPCS:84436)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Injection of drug or substance into vein (HCPCS:96374)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Injection, promethazine hcl, up to 50 mg (HCPCS:J2550)
• Phosphate level (HCPCS:84100)
• Folic acid level, serum (HCPCS:82746)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Alpha-fetoprotein (afp) level, serum (HCPCS:82105)
• Injection, furosemide, up to 20 mg (HCPCS:J1940)
• Red blood cell sedimentation rate, to detect inflammation, automated (HCPCS:85652)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection, lorazepam, 2 mg (HCPCS:J2060)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Blood creatinine level (HCPCS:82565)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)

The enumeration date for this NPI number is 11/16/2005 and was last updated on 3/10/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.